The terms of the agreement call for Israel-based Teva to maintain a controlling stake in the partnership, equal to 51% of the profits. For its majority ownership, Teva is responsible for the development and manufacture of medications, in addition to making available its global resources. Handok, founded in 1954, brings its sales and marketing distribution system to the partnership, and will also manage South Korea's regulatory affairs.